AI English summary of an SEC filing — figures as filed
Pfizer PFEThe company said total revenues decreased from $100.3 billion to $58.5 billion in 2023, a decline of $41.8 billion (42%). It cited significantly lower revenues from Comirnaty and Paxlovid as the main driver, including a non-cash revenue reversal of $3.5 billion for Paxlovid recorded in Q4.
Key points
AI summaryThe company said total revenues decreased from $100.3 billion to $58.5 billion in 2023, a decline of $41.8 billion (42%). It cited significantly lower revenues from Comirnaty and Paxlovid as the main driver, including a non-cash revenue reversal of $3.5 billion for Paxlovid recorded in Q4.
Pfizer said total revenues excluding Comirnaty and Paxlovid rose 7% on an operational basis. The company cited higher revenues from Nurtec ODT/Vydura, Oxbryta, Abrysvo, the Vyndaqel family and Eliquis, and a decline in Ibrance.
The company said income from continuing operations before taxes fell $33.7 billion to $1.1 billion in 2023 from $34.7 billion in 2022. It cited lower revenues, higher intangible asset impairment charges, higher restructuring and acquisition-related costs, higher amortization of intangible assets and higher selling, informational and administrative expenses as factors.
Pfizer said it paid $43.4 billion, net of cash acquired, for the acquisition of Seagen in 2023. As part of the financing, it issued $31 billion of long-term debt in May 2023 and $8 billion of commercial paper in Q4.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $50.9B
- Net income
- $2.1B
- EPS
- $0.37
- Operating cash flow
- $8.7B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Total revenues fell to $58.5 billion in 2023 as Comirnaty and Paxlovid declined
The company said total revenues decreased from $100.3 billion to $58.5 billion in 2023, a decline of $41.8 billion (42%). It cited significantly lower revenues from Comirnaty and Paxlovid as the main driver, including a non-cash revenue reversal of $3.5 billion for Paxlovid recorded in Q4.
Source · Based on the MD&A text of the filing
Operational revenue up 7% excluding Comirnaty and Paxlovid
Pfizer said total revenues excluding Comirnaty and Paxlovid rose 7% on an operational basis. The company cited higher revenues from Nurtec ODT/Vydura, Oxbryta, Abrysvo, the Vyndaqel family and Eliquis, and a decline in Ibrance.
Source · Based on the MD&A text of the filing
Pre-tax income from continuing operations $1.1 billion
The company said income from continuing operations before taxes fell $33.7 billion to $1.1 billion in 2023 from $34.7 billion in 2022. It cited lower revenues, higher intangible asset impairment charges, higher restructuring and acquisition-related costs, higher amortization of intangible assets and higher selling, informational and administrative expenses as factors.
Source · Based on the MD&A text of the filing
Seagen acquisition payment of $43.4 billion and its financing
Pfizer said it paid $43.4 billion, net of cash acquired, for the acquisition of Seagen in 2023. As part of the financing, it issued $31 billion of long-term debt in May 2023 and $8 billion of commercial paper in Q4.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…